证券研究报告 2025 年 06 月 10 日 | 市场数据 | | | | --- | --- | --- | | 指数名称 | 收盘 | 涨跌% | | 上证指数 | 3399.77 | 0.43 | | 深证成指 | 10250.14 | 0.65 | | 创业板指 | 2061.29 | 1.07 | | 科创 50 | 997.61 | 0.60 | | 北证 50 | 1442.51 | 1.08 | A 股市场概览 【行业动态】Canalys：预计 2025 年 AI 手机渗透率将达到 34% 【公司跟踪】博晖创新（300318.SZ）：获人乳头瘤病毒基因分型检测试剂 盒医疗器械注册证 | 类别 | 总市值 | 流通市 | 市盈率 | 市净率 | | --- | --- | --- | --- | --- | | | (亿元) | 值(亿元) | PE | PB | | 上证指数 | 653953 | 511233 | 12.03 | 1.25 | | 深证成指 | 217839 | 184651 | 20.06 | 2.12 | | 创业板指 | 58344 | 46026 | 27.07 | ...

Core Viewpoint - The company has received an acceptance notification from the National Medical Products Administration for its IND application of HSK47977, a new oral small molecule anti-tumor drug aimed at treating lymphoma, marking a significant step in its drug development pipeline [1] Group 1 - HSK47977 is a self-developed drug with no other drugs targeting the same pathway currently in clinical stages globally [1] - Preclinical studies show that HSK47977 exhibits significant proliferation inhibition on human lymphoma cell lines in vitro and effectively suppresses tumor growth in in vivo xenograft models [1] - The drug demonstrates strong target selectivity and an ideal safety window, potentially providing new treatment options for lymphoma patients [1]